氨茶碱与纳洛酮合用对新生儿重症疾病合并呼吸抑制的实效性探究

Effectiveness of aminophylline combining with naloxone for neonatal severe disease and respiratory depression

目的观察并探讨氨茶碱(aminophylline,Ami)与纳洛酮(naloxone,Nal)合用对重症疾病并呼吸抑制(respiratory depression,RD)的治疗价值。方法选择自2013年6月—2015年6月在浙江普陀医院接受治疗的重症疾病并RD新生儿84例,按照随机数字法将84例新生儿分为2组,观察组和对照组各42例,对照组单独采用Ami治疗,观察组在对照组基础上联合Nal治疗。对2组治疗前后呼吸频率(respiratory rate,RR)、呼气末CO2压力(Pet CO2)和脉搏血氧饱和度(SPO2)进行比较,并评价综合疗效,统计不良反应发生情况。结果治疗前,2组RR、Pet CO2和SPO2相比,差异无统计学意义(P>0.05);治疗后,观察组RR、Pet CO2和SPO2分别为(15.2±1.8)次/min、(42.7±5.2)mm Hg(1 mm Hg=0.133 k Pa)和(99.3±1.3)%,对照组为(12.4±1.3)次/min、(48.5±5.8)mm Hg和(99.6±0.9)%,观察组RR明显高于对照组,Pet CO2明显低于对照组(P<0.05);观察组总有效率为88.0%(37/42),对照组为69.0%(29/42),2组相比差异具有统计学意义(P<0.05);2组不良反应发生率相比,差异无统计学意义(P>0.05)。结论 Ami与Nal联合能明显改善新生儿重症疾病并呼吸抑制的呼吸抑制情况,效果显著,且无明显副作用,是治疗新生儿重症疾病并呼吸抑制安全有效的方案。

Objective To observe and explore the effectiveness of aminophylline （Ami） combining with naloxone （Nal） for neonatal severe disease and respiratory depression. Methods Total 84 Neonatal severe disease and respiratory depres- sion accepted drug treatment in this hospital during June, 2013 to June, 2015 were selected, and were divided into two groups accorded to the random number method,42 cases in each group, the control group was treated with Oral Ami, while the observation group was treated with Nal on the basis of the control group. Respiratory rate （RR）, end-tidal CO2 pressure （ PetCO2 ） and pulse oximetry （ SPO2 ） before and after treatment as well as incidence of adverse reactions were recorded and compared, and comprehensive efficacy were evaluated. Results The difference of RR, PetCO2 and SPO2 before treatment was not statistically significant（P 〉 0.05 ） ;after treatment, RR, PetCO2 and SPO2 in the observation group were （15.2±1.8） times/min,（42.7 ±5.2） mm Hg （1 mm Hg=0. 133 kPa） and （99.3 ±1.3）%,while was （ 12.4 ± 1.3 ） times/min, （48.5 ± 5.8 ） mm Hg and （99.6 ± 0.9 ） % in the control group, RR in observation group were significantly higher than the control group, while PetCO2 were significantly lower than the control group （ P 〈 0.05 ） ; total effective rate was 88.0% （37/42） in observation group, while was 69.0% （29/42） in the control group, the difference was statistically significant（ P 〈 0.05 ） ;the difference of adverse reactions ineidence between the two groups was not statistically significant（P 〉 0.05 ）. Conclusion Ami and Nal can improve respiratory depression in neonatal intensive dis- ease and respiratory depression, the effect is significant, and no significant side effects, thus it is a safe and effective solu- tion for the Neonatal severe disease and respiratory depression.